“Peptide” has become a catch-all term in longevity and wellness medicine, but the label can obscure more than it explains.
Some peptide-based medications are FDA-approved prescription drugs with established indications. Others are investigational drug candidates. Still others are bulk substances being evaluated within the federal compounding framework. Those distinctions matter because popularity, pharmacy availability, or online advertising do not by themselves establish that a substance is lawfully available or supported by adequate clinical evidence.
Peptide categories patients commonly encounter
FDA-approved peptide-based medications
Some established prescription drugs are peptides or peptide analogs. Their use is governed by their individual indication, evidence, safety profile, and the patient’s clinical circumstances. The existence of an approved peptide medication does not make unrelated peptides interchangeable with it.
Recovery peptides: BPC-157 and TB-500
BPC-157 and TB-500 are frequently promoted online for injury recovery and tissue healing. They remain subjects of scientific and regulatory interest, but they are not currently offered by Empower Med. Federal review of related bulk substances is not the same as FDA drug approval and does not automatically permit routine compounding.
Growth-hormone pathway compounds
Products affecting growth-hormone pathways vary substantially in regulatory status. FDA-approved medications should not be grouped together with investigational or non-approved compounds simply because their biological pathways overlap. CJC-1295 and ipamorelin are not currently offered by Empower Med.
MOTS-c, injectable GHK-Cu and related emerging compounds
These compounds are discussed widely in longevity settings, but human evidence, safety information, and regulatory status differ considerably. They are not currently offered by Empower Med.
Investigational metabolic drugs
Retatrutide, cagrilintide, and other drugs still in clinical development should not be confused with FDA-approved metabolic therapies. Investigational drug candidates are not currently offered by Empower Med.
How Empower Med evaluates an emerging therapy
Before an emerging treatment could become part of clinical care, Dr. Everson considers lawful availability, the quality of human evidence, known and uncertain risks, medication source, interactions with existing conditions and medications, and whether an established therapy is better supported.
That may lead to a simple answer: the treatment is interesting, but it is not appropriate or available for clinical use today.
What “under regulatory review” actually means
A federal advisory review or discussion of a bulk drug substance does not itself constitute FDA approval and does not automatically make a compound lawful for routine clinical compounding. Regulatory status can change, which is why Empower Med monitors the field rather than promising future availability.
The practical takeaway
If you encounter a peptide or emerging therapy online, ask four questions: Is it FDA-approved for the proposed use? If compounded, is the compounding pathway lawful? What human evidence supports the claimed benefit? What meaningful safety information exists?
New and popular are not clinical indications.